Search results for " Liv"

showing 10 items of 2456 documents

Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis

2020

International audience; Kupffer cells (KCs) are liver-resident macrophages that self-renew by proliferation in the adult independently from monocytes. However, how they are maintained during non-alcoholic steatohepatitis (NASH) remains ill defined. We found that a fraction of KCs derived from Ly-6C+ monocytes during NASH, underlying impaired KC self-renewal. Monocyte-derived KCs (MoKCs) gradually seeded the KC pool as disease progressed in a response to embryo-derived KC (EmKC) death. Those MoKCs were partly immature and exhibited a pro-inflammatory status compared to EmKCs. Yet, they engrafted the KC pool for the long term as they remained following disease regression while acquiring matur…

0301 basic medicine[SDV]Life Sciences [q-bio]OntogenyMESH: Cell Self RenewalSelf renewalMESH: MonocytesMESH: Mice KnockoutMice0302 clinical medicineNon-alcoholic Fatty Liver DiseaseImmunology and AllergyKupffer cellsMESH: AnimalsCell Self RenewalMESH: Lipid MetabolismMice KnockoutKupffer cellLipidsResearch Highlightmacrophages[SDV] Life Sciences [q-bio]Infectious Diseasesmedicine.anatomical_structureLiver030220 oncology & carcinogenesismonocytesmedicine.medical_specialtynon-alcoholic steatohepatitis (NASH)ImmunologyBiology03 medical and health sciencesMESH: Mice Inbred C57BLMESH: Cell ProliferationInternal medicinemedicineAnimalsLiver damageMESH: MiceCell ProliferationMESH: Non-alcoholic Fatty Liver DiseaseTriglyceride storageNon alcoholicLipid Metabolismmedicine.diseaseMESH: Lipidseye diseasesMice Inbred C57BLMESH: Kupffer Cells030104 developmental biologyEndocrinologySteatohepatitisHomeostasisMESH: LiverImmunity
researchProduct

Statins in liver disease: not only prevention of cardiovascular events

2018

Statins are lipid-lowering agents and one of the most pre-scribed drugs worldwide. Their main mechanism of action –inhibition of the mevalonate pathway through an effect on hydroxy-methylglutaryl CoA reductase, thus affecting the synthesis of cholesterol in the liver – makes this class of drugs pivotal in primary and secondary prevention of cardio-vascular risk, as extensively demonstrated in large prospective, randomized controlled trials. Along the years, we learned that the lower the better, and LDL-cholesterol targets have been progressively reduced to values ≤70 mg/dL for secondary prevention or in the presence of diabetes.

0301 basic medicinecardiovascular riskmedicine.medical_specialtydrug safetyGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineFatty livermedicineHumansHypolipidemic AgentsHepatologybusiness.industryFatty liverhydroxymethylglutaryl-CoA reductase inhibitorGastroenterologynon-alcoholic fatty liver diseaseHepatologymedicine.diseaseHydroxymethylglutaryl-CoA Reductase Inhibitors030104 developmental biologyCardiovascular DiseasesDisease Progressionlipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

2021

Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and age…

0301 basic medicinehepatotoxicityNevirapineEfavirenzQH301-705.5030106 microbiologyEtravirinecARTReviewBioinformaticsliver03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineDoravirinemedicineAnimalsHumans030212 general & internal medicineBiology (General)antiretroviral drugsbusiness.industryFatty livervirus diseasesHIVGeneral Medicinemedicine.diseasechemistryRilpivirineChronic DiseaseReverse Transcriptase InhibitorsDrug Therapy CombinationDILIChemical and Drug Induced Liver InjuryViral hepatitisbusinessmedicine.drugCells
researchProduct

Serum vitamin D and functional impairment in octogenarian women.

2016

Abstract Purpose Serum vitamin D deficiency has been associated with frailty in people aged 65 and over, however its relationship with functional impairment has not been investigated in octogenerian (aged 80–90 years) institutionalized women. Methods We assessed functional impairment in this latter group by measuring frailty syndrome and other geriatric and psychological assessment scales: the Tinetti gait and balance index to determine the risk for falls, the Barthel index to measure the basic activities of daily living, the Lawton index for instrumental activities, the mini-mental score examination test for cognitive impairment, the Yesavage scale for geriatric depression, and the Norton …

0301 basic medicinemedicine.medical_specialtyActivities of daily livingFrail ElderlyFrailty syndrome03 medical and health sciences0302 clinical medicineInternal medicinemedicineVitamin D and neurologyHumansPsychological testing030212 general & internal medicineVitamin DGeneral NursingDepression (differential diagnoses)AgedAged 80 and over030109 nutrition & dieteticsbusiness.industryTinetti testmedicine.diseaseGaitAgeingPhysical therapyFemalebusinessApplied nursing research : ANR
researchProduct

Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease

2021

AbstractGastrointestinal diseases such as celiac disease, functional gastrointestinal disorders (FGIDs), inflammatory bowel disease (IBDs) and acute or chronic diarrhea are quite frequent in the pediatric population. The approach, the diagnosis and management can be changed in the 2019 coronavirus disease (COVID-19) pandemic era. This review has focused on: i) the current understanding of digestive involvement in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected children and adolescents and the clinical implications of COVID-19 for pediatric gastroenterologists, ii) the impact of COVID-19 on the clinical approach to patients with pre-existing or onset diseases, including…

0301 basic medicinemedicine.medical_specialtyAdolescentGastrointestinal Diseasesmedicine.medical_treatmentFunctional gastrointestinal disordersACE2ReviewDiseaseChronic liver diseaseInflammatory bowel diseaseDigestive endoscopyPediatricsGastrointestinal symptomsInflammatory bowel disease03 medical and health sciencesLiver diseaseFunctional gastrointestinal disorder0302 clinical medicineACE2; COVID-19; Digestive endoscopy; Functional gastrointestinal disorders; Gastrointestinal symptoms; Inflammatory bowel disease; Liver disease; Pediatrics; Adolescent; COVID-19; Child; Gastrointestinal Diseases; Humans; Infection Control; SARS-CoV-2Gastrointestinal symptomPandemicmedicineHumansRisk factorIntensive care medicineChildInfection Controlbusiness.industrySARS-CoV-2lcsh:RJ1-570COVID-19lcsh:PediatricsImmunosuppressionmedicine.disease030104 developmental biologyGastrointestinal disease030211 gastroenterology & hepatologybusinessLiver disease
researchProduct

2021

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with no therapeutic consensus. Oxidation and inflammation are hallmarks in the progression of this complex disease, which also involves interactions between the genetic background and the environment. Mastiha is a natural nutritional supplement known to possess antioxidant and anti-inflammatory properties. This study investigated how a 6-month Mastiha supplementation (2.1 g/day) could impact the antioxidant and inflammatory status of patients with NAFLD, and whether genetic variants significantly mediate these effects. We recruited 98 patients with obesity (BMI ≥ 30 kg/m2) and NAFLD and randomly allocated them to eit…

0301 basic medicinemedicine.medical_specialtyAntioxidantbusiness.industrymedicine.medical_treatmentImmunologyFatty liverDiseasemedicine.diseaseObesityGastroenterologyNutrigeneticsGZMB03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicineInternal medicinemedicineImmunology and Allergy030211 gastroenterology & hepatologybusinessTGFBIFrontiers in Immunology
researchProduct

Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.

2016

Background & Aims The pathomechanisms underlying non-alcoholic fatty liver disease (NAFLD) and the involved molecular regulators are incompletely explored. The nuclear factor-kappa B (NF-κB)-cofactor gene B cell leukemia-3 ( Bcl-3 ) plays a critical role in altering the transcriptional capacity of NF-κB – a key inducer of inflammation – but also of genes involved in cellular energy metabolism. Methods To define the role of Bcl-3 in non-alcoholic steatohepatitis (NASH), we developed a novel transgenic mouse model with hepatocyte-specific overexpression of Bcl-3 ( Bcl-3 Hep ) and employed a high-fat, high-carbohydrate dietary feeding model. To characterize the transgenic model, deep RNA seque…

0301 basic medicinemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentBiology03 medical and health sciencesLiver diseaseMice0302 clinical medicineB-Cell Lymphoma 3 ProteinInternal medicineProto-Oncogene ProteinsmedicineAnimalsHumansInsulinInflammationHepatologyInsulinLiver cellFatty liverLiver Neoplasmsmedicine.disease030104 developmental biologyEndocrinology030220 oncology & carcinogenesisLipogenesisSteatohepatitisSteatosisTranscription FactorsJournal of hepatology
researchProduct

Hepatic benefits of HCV cure

2020

Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to improved outcomes at all stages of liver disease. However, available data suggest that the maximum measurable benefit is obtained by treating patients before they reach the stage of compensated advanced chronic liver disease (cACLD). Ideally, all patients with chronic hepatitis C should be treated before they develop advanced fibrosis or cirrhosis, since even if sustained virologic response (SVR) reduces the risk of hepatic events (e.g. decompensation and hepatocellular carcinoma [HCC]) and improves survival, further progression of liver disease and adverse outcomes, including hepatic deaths, cannot be entirely avoided…

0301 basic medicinemedicine.medical_specialtyCirrhosisHepatocellular carcinomaPortal venous pressureSurvival.Chronic liver diseaseGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineDecompensationCirrhosiHepatologybusiness.industryHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologyHepatocellular carcinomaPortal hypertension030211 gastroenterology & hepatologybusiness
researchProduct

Genetic contribution to alcohol dependence: Investigation of a heterogeneous german sample of individuals with alcohol dependence, chronic alcoholic …

2017

The present study investigated the genetic contribution to alcohol dependence (AD) using genome-wide association data from three German samples. These comprised patients with: (i) AD; (ii) chronic alcoholic pancreatitis (ACP); and (iii) alcohol-related liver cirrhosis (ALC). Single marker, gene-based, and pathway analyses were conducted. A significant association was detected for the ADH1B locus in a gene-based approach (puncorrected = 1.2 × 10-6; pcorrected = 0.020). This was driven by the AD subsample. No association with ADH1B was found in the combined ACP + ALC sample. On first inspection, this seems surprising, since ADH1B is a robustly replicated risk gene for AD and may therefore be …

0301 basic medicinemedicine.medical_specialtyCirrhosislcsh:QH426-470alcohol dependenceMedizinGenome-wide association studyLocus (genetics)610 Medicine & healthGastroenterologyArticle03 medical and health sciencesLiver diseaseInternal medicineGeneticsMedicine610 Medicine &amp; healthAllele frequencyGenetics (clinical)genome-wide association studybusiness.industryAlcohol dependencealcohol dehydrogenaseADH1Bchronic alcoholic pancreatitisalcohol dependence; chronic alcoholic pancreatitis; alcoholic liver cirrhosis; genome-wide association study; alcohol dehydrogenase; <i>ADH1B</i>; <i>ADH1C</i>medicine.diseaseADH1CADH1Blcsh:Genetics030104 developmental biologyPancreatitisalcoholic liver cirrhosisbusiness
researchProduct